Page 38 - Merck Sharp News Today

There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis.

Applications are open for early and growth-stage health tech innovators Pharmacy Drugstore Counter: Portrait of Helpful Black Male Pharmacist Talking on the Mobile Phone with Customer, Giving Medicine Recommendation, Uses Computer, Checks Prescription Drugs Availability LAGOS, Nigeria, 25 April, 2023 -/African Media Agency(AMA)/-  Investing in Innovation Africa (i3), a pan-African initiative for start-ups building the future of […]

/PRNewswire/ -- DelveInsights FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors...

The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety

The novel ataxia telangiectasia–mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.

Andrea Necchi, MD, discusses the efficacy and safety data reported from the FIDES-02 study, explains the clinical relevance of these data despite the trial’s negative result, and highlights several other influential studies presented at the 2023 Genitourinary Cancers Symposium.

HPV Vaccine Caused Cervical Cancer in Young Woman, Lawsuit Alleges

Applications are open for early and growth-stage health tech innovators

Applications are open for early and growth-stage health tech innovators

Applications are open for early and growth-stage health tech innovators